FDA Approvals in Oncology: July-September 2026
During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options...
Author:
Cancer Research Catalyst Staff
During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options...
The second installment of Cancer Research Catalyst’s new monthly series, “Unboxing Cancer News,” highlights exciting cancer research discoveries reported...
The September Editors’ Picks from AACR's peer-reviewed journals include insights into cancer evolution in leukemia, a strategy for overcoming...
Cancer Research Catalyst has launched a new monthly series, “Unboxing Cancer News,” that highlights exciting cancer research discoveries. Read...
Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution,...
At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed how...
During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment...
The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma...